Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines

Area of Science:

• Immunology
• Vaccinology
• Respiratory Medicine

Background:

• Tuberculosis (TB) is a leading global infectious disease.
• The current Bacille Calmette-Guérin (BCG) vaccine offers limited protection against adult pulmonary TB.
• Intradermal BCG injection is standard, but lung delivery may enhance immune response.

Purpose of the Study:

• To explore the potential of repurposing existing inhalation devices for mucosal delivery of live attenuated TB vaccines.
• To discuss the feasibility of using devices like the mucosal atomization device (MAD) syringe and Respimat Soft Mist inhaler for TB vaccine delivery.

Main Methods:

• Review of existing literature on inhalation therapy and TB vaccine delivery.
• Discussion of two specific repurposed devices: MAD syringe and Respimat Soft Mist inhaler.
• Identification of challenges and research questions for respiratory delivery of TB vaccines.

Main Results:

• Inhalation delivery of BCG directly to the lungs shows promise for enhanced immune responses.
• Existing devices like MAD and Respimat are potential candidates for repurposing.
• Further research is needed to confirm efficacy and accessibility.

Conclusions:

• Repurposing inhalation devices offers a novel strategy for improving TB vaccine efficacy.
• Respiratory delivery of live attenuated TB vaccines could overcome limitations of current BCG vaccination.
• Cost-effective and accessible devices are crucial for TB-endemic regions.